Novavax. thank the I'm with this first leadership And helping of you the Erika. in you, my be us all team, in to together Board, employees. our earnings Thank call joining And pleased with with for excited chapter our for to I'm company's and all partnership to history, today. of new you shape have of our everyone honour
having the vaccine, potential additional organization. different which years few to that key led validated has and their adjuvant me pharmaceutical XX offer to including significant there mature their assets spending the that entities, commercial industry, M pipeline organizations factors for a growth Novavax, drew technology matrix and drew and a to the XX platform, effective several of in COVID and become innovative of together differentiated After create value the are a me produced
execution mission company values, integrated from driven and have and people capabilities, global And health. fully public discovery manufacturing, global a improving commercial of are to There culture set scale. Novavax’s dedicated ranging to a finally which on cultivated
the it priorities previous share before to our from handing near five a results like over and term would members quarter. my at I discuss Today, of our first our additional team to company the leadership insights weeks to outline few from
our gaining five Novavax organization. perspective my time the spent weeks. stakeholders during about listening, my about in late talk the and let's across learning I've observations first January, business joining Since from So key
partners. insights, to and will and months global early business, amazing an the come to gather picture to and customers and gain they of initial our I our as some and initial current of in weeks for certainly our had Though meet challenges. our employees, listen all our continue facilities I've to visit chance learn these capabilities,
These early it best us and interactions to need believe to made organization entire me that XXXX. have for we I key will on priorities, success give focus a few clear the our which chance
company capability and Importantly, to to date. long by and they the leveraging we the remarkable have as have me we also reinforced set that build term the been that technology, have value to talent laid opportunity foundation has a
our talk a let's So about and take near priorities. term moment
made necessary global were product complex pandemic. the While company to investments the the over for deliver Novavax our to during a years build significant commercial past three first
We are commercial pandemic an traditional emerging settles face. the a market as endemic now more into seeing
emerging better plans to commercial our company new the require of will our This align our with adjust level investment market to this opportunity. and efforts
in while actions this In we with These are together that the during time term longer be no my to our in few fact, that those the at most weeks, decisive leadership efforts first intended focus may success, to reducing believe taken our resource our goals. have I areas same important and commitments spend, actions mind. the near team on are and aligned already things our with
one, already priorities minutes arrival. a upcoming the we've like share some taken I'd vaccination my competitive a the few take actions with and season. to product these Priority deliver XXXX since you for fall of to
with global intention an and recommendations. updated that is COVID to a aligns deliver are vaccine company, our public health We
intend product are move overtime. markets we these our to this ensure intended to a to are which we orientation make commercial in help to positioned purchase important agreement compete for advanced an Together as well smaller available is from dose factors files, Additionally, we customers. know
upcoming for do we vaccine. will selection important update fall globally, as strain Importantly, we on clarity yet have our be not season, vaccination an which factor full us for XX the
need of selection, we order the deliver In manufacturing US, process nuances including timing vaccine. own what with in as a partnership our our we example, to them of will the in for inform and to protein based strain product, FDA about working are the the
structure. flow evolve and our manage move our scale Reduce Let's of cash priority on and to rate two. our spend,
Since my reduce priorities, align with delivering term to arrival, spend our of successful focus rate this near and fall. our have the investments taken intent better launch our of energy a immediate and with efforts steps our we
us us long I release. efficiently have our already press taken term evolve the to better our important internal changes an leadership of modifying initial our resources, will success. discussed executive by operate in which structure for and to position align our step we earnings organization helped allow more to These team,
disease, Chief O'Hara on and business Pfizer. vaccines America organization over XX focus Alliance these Strategic years Otsuka corporate and who in new brings Commercial North including roles leadership as experience include Officer Sanofi Commercial will the to of development, Chief changes of Strategy Highlights senior Officer of both the vaccines and appointment strategy and and and portfolio Elaine for in Elaine infectious at our management. senior
In with policy Dr. adviser Taylor, Filip Dr. Glenn. expanded addition, and Silvia a and of government responsibility move Greg Right Dubovsky to Affairs Research following will who’s Chief a into retirement role the of President the consulting Officer we'll affairs, Development, the R&D strategic Advocacy Corporate and advocacy. company. a including as assume role
focus report Kelly, his move as Troy under relations Chief will on to Morgan, And me CFO directly Jim remain changes. among now and will order investor in in compliance. Officer our role our CEO to our other Compliance finally, company's elevate
with coming any term during we these in the future our you additional to In long and assessing changes months, will with structure more creation in potential priorities global sharing mind, be detail and forward calls. value look
Jim You later beyond will assets and additional are alone. And Kelly, more from reducing value finally, in we investments platform, the call. hear new priority leverage about technology three, our streamlining capabilities, to today our our portfolio of drive how our and
Beyond a with for term opportunity vaccination near the XX a campaign, differentiated portfolio global vaccine fully integrated of data and creation. that assets, we footprint set a opportunity platform, COVID vaccine our expected X, a mid-year, Phase presents capability fall and for promising COVID-XX with value influenza significant ‘XX including technology a combination in have the
licensing, the and include and to over term strategies, but development. capabilities, our have added intention resources both to new other to chief I this role strategy out mentioned of could our or co-promotion in corporate for different objective, and is the officer further of earlier. potential against the potential as align To via related these including activities. my unlock team limited not and partnering, the business assets This executive near It time,
prioritize pipeline, role, our a assessment Elaine will of pipeline be part will we an As how a investments. of review of strategic undertaking including our
more decided to pause discuss will on have in detail. already clinical Phillip RSV, which We development
comments, impressed a I in can during have at of our business, Novavax. trying know is continue As learn and lot say the I much with get learn have sure talent energy I as I as to although to been been noted already, team. that for weeks I first have still to few my to as what can And my opening I truly this
with we and remarkable scale, that a value importantly, and the set future an of built growth assets our opportunity capabilities this Impressed significant global have and and the technology organization on as represents. for
and although both aware as to well commitment along our the and time, And about years disappointments. same the humility that way, challenges challenges as like pledge the company achieved At we focusing we along near also perspective and priorities a our the face. moment would provide to today over the our future about to have lows. have journey, has to we some successes admit to I'm highs many with take you and balance on I to are this experienced experienced we few the transparent past opportunities term be
well The and to for to consumers faith new as and easy. vaccine some to I your in opportunity, be future. And ahead But commit of with say and like significant we be a would path you towards all And opportunity. for our partners, a investors, this goal the And patience lead energy won't effort of our down Novavax us. success. exciting all as it and potential as our your our thank give road our filled a will now of we you with challenges.
along to we if our correct work belief path thankful your And potential. made hard way. for But the we we'll and and do, continuously through be fall our
strengthening let months, our growth in to a the a future a priorities goal strong maintaining So success. committed in coming good with the we in saying close today of you company on the us and focus opening near I as and position with putting position shared are me my by the for term, comments
to would like over I on on the to beginning update detail, an five. John? Trizzino, with our that, results activities provide team to it With commercial discuss our Slide to hand more John in
